Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO

Needham & Company highlighted Seattle Genetics (Nasdaq: SGEN), Pharmacyclics (Nasdaq: PCYC) and Dendreon (Nasdaq: DNDN) after reviewing ASCO abstracts.

Seattle Genetics: We believe the ASCO Mtg data may give an indication of the potential treatment duration in the real world and ADCETRIS as a potential curative treatment for HL and sALCL patients

Pharmacyclics: We believe the data will further demonstrate the robustness of the efficacy of PCI-32765 in a more focused CLL population with a much larger clinical trial patient population... We believe PCI-32765 is an active agent with a good tolerability profile, allowing the potential for development as a single agent as well as add-on treatment to current SOC therapy.

Dendreon: We believe these results will provide support for potential effect of PROVENGE on other clinically relevant endpoints other than overall survival...We believe the PROVENGE clinical benefit is well established. We believe the Company is on track to meet or beat its own revenue guidance.

Abstracts are posted at http://abstract.asco.org/

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Needham Reiterates Buy Rating on Napco Security Technologies, Inc. (NSSC)